WALTHAM, Mass., July 28, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 3, 2021. Second Quarter 2021 Highlights Second quarter revenue increased 34% to $9.27 billion. Second quarter GAAP diluted earnings per share (EPS) increased 59% to... Read more
Revenue of $1.228 billion; 51% reported growth; 41% organic growth GAAP EPS from continuing operations of $2.19; Adjusted EPS of $2.83 Initiates Third Quarter and Raises Full-Year Revenue and Earnings Guidance Announces Agreement to Acquire BioLegend – Leading Antibody & Research Reagent Provider Earnings Call Moved to Today at 8:00 a.m. Eastern Time; Dial-in Information... Read more
Transformative deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine Leader in antibody development with highly complementary, innovative portfolio in emerging, high-growth areas of biologics, cell and gene therapy, proteogenomics, and recombinant proteins Commercial synergy opportunity to accelerate life science growth with potential benefits for diagnostics franchise Annual BioLegend... Read more
WASHINGTON, July 22, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the second quarter 2021. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended July 2, 2021, net earnings were $1.7 billion, or $2.28 per diluted common share which represents an 84.0% year-over-year... Read more
Every year in the US, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS), and there remains a high unmet need for new treatment options1 The designation is based on interim results from the phase Ib M15-531 study investigating Venclexta/Venclyxto plus azacitidine in people with previously untreated higher-risk MDS This is the 11th Breakthrough Therapy... Read more
Technology leaders combine expertise for very low-temperature Raman imaging Ulm, Germany – Haar, Germany July 20, 2021 Raman imaging innovator WITec GmbH and cryogenic microscopy specialist attocube systems AG have jointly introduced cryoRaman. This cryogenic Raman imaging system integrates attocube’s leading-edge cryostat and nanopositioner technology with the vaunted sensitivity and modularity of WITec’s alpha300 correlative... Read more
Final analysis from the phase IIIb STASEY study, including data from 193 people with haemophilia A, further support the benefit/risk profile of Hemlibra, with no new safety signals identified1 STASEY is one of the largest open-label studies primarily assessing safety and tolerability of a medicine for people with haemophilia A with factor VIII inhibitors Hemlibra... Read more
Tuberculosis is a disease of poverty, and economic distress with 1.4 million deaths annually1 and the growing challenge of drug resistance is adding to the global health crisis WHO guidelines support the expansion of tuberculosis diagnostics in resource-limited countries, enabling patients to receive timely diagnosis leading to proper treatment, which benefits their recovery and slows... Read more
Roche will present the final analysis from the phase IIIb STASEY study, reinforcing the safety and efficacy profile of Hemlibra in a broad range of people with haemophilia A with factor VIII inhibitors1 Spark Therapeutics will share updated data from the ongoing phase I/II clinical trial of investigational gene therapy SPK-8011, demonstrating that hepatocyte expression... Read more
WITec combines antibunching experiments with fast Raman and photoluminescence imaging. Single-photon emitters have quantum mechanical properties that are exploited in quantum technology and information science, including the development of quantum computers and cryptography methods. Nitrogen vacancy (NV) centers in diamonds, single fluorescent molecules, carbon nanotubes and quantum dots are prominent examples of single-photon emitters. In... Read more